Partnership with Swinburne & Cooper Investors

Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.

Partnership with Swinburne & Cooper Investors

September 23, 2021
Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.
Read Transcript

Swinburne’s Centre for Human Psychopharmacology has received a further $1 million in philanthropic funding for their research, which will use the latest neuroimaging technology.

In summary:

  • Swinburne has received a transformational commitment of $1 million from Hearts and Minds Investments Ltd to support key mental health medical research
  • Funding will support programs to boost emotional intelligence (EI) in lower socioeconomic status primary and secondary schools, and explore the connection between the gut microbiome and cognitive decline
  • Researchers from Swinburne’s Centre for Human Psychopharmacology will blend fundamental research with the latest technologies to deliver key advances for mental health

 

Swinburne has signed a new agreement with Hearts and Minds Investments Ltd and Cooper Investors that will see a further $1 million invested into medical research by 2023. This takes the total investment from Hearts and Minds Investments Ltd to $1.7 million.

The gift will support research by Swinburne’s Centre for Human Psychopharmacology into improving emotional intelligence (EI) in schools, as well as the link between gut microbiome and healthy cognitive ageing.

 

Delivering lasting impact

Swinburne’s Centre for Human Psychopharmacology brings together institutions from around the globe and uses the latest technologies and research methodologies to develop new medicine and drive a new generation of medical research in Australia.

The research will apply scientific rigour and the latest technology to research biological determinants of cognitive health across one's lifespan. It will also include trials with Swinburne’s bespoke neuroimaging capability and interactive online research programs for participants.  The research supports Swinburne’s vision of bringing people and technology together to build a better world.

Swinburne’s Vice-Chancellor and President, Professor Pascale Quester, says the benefits of the research, made possible by support from Hearts and Minds and Cooper Investors, will be felt for generations to come.

‘Swinburne is proud to be partnering with Cooper Investors and Hearts and Minds. This investment will support early career researchers and enable them to make real advances in key areas of health and medical research,’ Professor Quester says.

‘Blending human insight and endeavour with technology, this research will help understand how the health of our microbiome affects cognitive decline as we age, and we can explore how to drive school retention and performance through increased emotional intelligence.  It is vital research like this that is helping us achieve our vision of bringing humans and technology together to build a better world.’

 

Investing in our future

Since 2019, the philanthropic partnership between Swinburne and Hearts and Minds has contributed to the overall improvement of mental health, intuition and wellbeing of Australians.

CEO of Hearts and Minds Investments Ltd and Swinburne alum, Paul Rayson, says the organisation has a passion for growing sustainable, progressive partnerships, like the one with Swinburne.

‘Investing in research is investing in our future – a long-term investment into making the world a better place,’ Rayson says.

‘There are many quality of life issues that can be enhanced by a better understanding of human cognition, mood and behaviour. We see the world-class research conducted at Swinburne as having the potential to make a positive impact and lead to improved treatments and management of cognitive health,’ he says.

‘When it comes to medical research, everyone is hoping to get that breakthrough, which can be rare, but when you do get it – it has a huge benefit.’

Cooper Investors, that nominated Swinburne as a beneficiary for Hearts and Minds funds, said: ‘Philanthropy or the act of contribution is a core value at Cooper Investors.’

‘We recognise mental health as the health challenge of a generation and believe that, wherever possible, we should look to support institutions like Swinburne to conduct vital translational research in this area. We want to use our philanthropy program to support world-class research and programs to better the mental health of communities across the country.’

 

 

Swinburne’s Centre for Human Psychopharmacology has received a further $1 million in philanthropic funding for their research, which will use the latest neuroimaging technology.

In summary:

  • Swinburne has received a transformational commitment of $1 million from Hearts and Minds Investments Ltd to support key mental health medical research
  • Funding will support programs to boost emotional intelligence (EI) in lower socioeconomic status primary and secondary schools, and explore the connection between the gut microbiome and cognitive decline
  • Researchers from Swinburne’s Centre for Human Psychopharmacology will blend fundamental research with the latest technologies to deliver key advances for mental health

 

Swinburne has signed a new agreement with Hearts and Minds Investments Ltd and Cooper Investors that will see a further $1 million invested into medical research by 2023. This takes the total investment from Hearts and Minds Investments Ltd to $1.7 million.

The gift will support research by Swinburne’s Centre for Human Psychopharmacology into improving emotional intelligence (EI) in schools, as well as the link between gut microbiome and healthy cognitive ageing.

 

Delivering lasting impact

Swinburne’s Centre for Human Psychopharmacology brings together institutions from around the globe and uses the latest technologies and research methodologies to develop new medicine and drive a new generation of medical research in Australia.

The research will apply scientific rigour and the latest technology to research biological determinants of cognitive health across one's lifespan. It will also include trials with Swinburne’s bespoke neuroimaging capability and interactive online research programs for participants.  The research supports Swinburne’s vision of bringing people and technology together to build a better world.

Swinburne’s Vice-Chancellor and President, Professor Pascale Quester, says the benefits of the research, made possible by support from Hearts and Minds and Cooper Investors, will be felt for generations to come.

‘Swinburne is proud to be partnering with Cooper Investors and Hearts and Minds. This investment will support early career researchers and enable them to make real advances in key areas of health and medical research,’ Professor Quester says.

‘Blending human insight and endeavour with technology, this research will help understand how the health of our microbiome affects cognitive decline as we age, and we can explore how to drive school retention and performance through increased emotional intelligence.  It is vital research like this that is helping us achieve our vision of bringing humans and technology together to build a better world.’

 

Investing in our future

Since 2019, the philanthropic partnership between Swinburne and Hearts and Minds has contributed to the overall improvement of mental health, intuition and wellbeing of Australians.

CEO of Hearts and Minds Investments Ltd and Swinburne alum, Paul Rayson, says the organisation has a passion for growing sustainable, progressive partnerships, like the one with Swinburne.

‘Investing in research is investing in our future – a long-term investment into making the world a better place,’ Rayson says.

‘There are many quality of life issues that can be enhanced by a better understanding of human cognition, mood and behaviour. We see the world-class research conducted at Swinburne as having the potential to make a positive impact and lead to improved treatments and management of cognitive health,’ he says.

‘When it comes to medical research, everyone is hoping to get that breakthrough, which can be rare, but when you do get it – it has a huge benefit.’

Cooper Investors, that nominated Swinburne as a beneficiary for Hearts and Minds funds, said: ‘Philanthropy or the act of contribution is a core value at Cooper Investors.’

‘We recognise mental health as the health challenge of a generation and believe that, wherever possible, we should look to support institutions like Swinburne to conduct vital translational research in this area. We want to use our philanthropy program to support world-class research and programs to better the mental health of communities across the country.’

 

 

Disclaimer: This material has been prepared by Swinburne's Centre For Human Psychopharmacology, published on Sep 23, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
August 31, 2020

Dysfunctional' mental health system needs boost in wake of pandemic: experts

Experts are warning the current mental health system is ill-equipped to respond to a forecast 30 per cent spike in mental illness in the wake of the coronavirus pandemic.

Read More
August 10, 2020

Beneficiary Profile: RPA Green Light

Emergency departments are the frontline of health care, with one in seven Australians seeking help from a hospital emergency department every year. Our medical staff depend on research findings to help inform their responses to urgent patient needs.

Read More
June 25, 2020

Understanding biomarkers of cognition in the elderly

Swinburne researchers have been investigating the biomarkers for cognitive ageing in healthy elderly Australians to examine whether age associated cognitive decline can be reduced.

Read More
June 18, 2020

Settling the Mind: Mental Health and Coronavirus Webinar Series

The Black Dog Institute has put together a webinar series called "Settling the Mind", which shares evidence-based insights and resources to help you navigate the affects of Covid.

Read More
June 16, 2020

Charlie Teo Foundation: How hope keeps them going

The Charlie Teo Foundation takes a moment to celebrate 2 years of the Foundation (CTF) and the exciting projects they are funding to help in their fight against brain cancer.

Read More
June 9, 2020

Beneficiary Profile: Orygen

1 in 5 young people will have experienced a depressive episode by the time they are 18. With thanks to Cooper Investors and Hearts & Minds, we have been able to put youth mental health on the global agenda and progress our work in developing a global mental health framework.

Read More
May 3, 2020

New treatment giving severe COVID-19 patients a fighting chance

The Victor Chang Cardiac Research Institute featured on 7News discussing their latest Covid-19 collaborative project.

Read More
April 5, 2020

Victor Chang's Executive Director discusses the impact of Covid-19

Victor Chang Cardiac Research Institute's Executive Director Professor Jason Kovacic discusses Covid-19, its impact on the heart and their related research.

Read More
April 2, 2020

Coronavirus: Anxiety, Stress & Wellbeing

Black Dog Institute, one of our beneficiaries, has put together helpful, evidenced-based resources to help you, your workplaces, schools and parents during this time.

Read More
November 22, 2019

Impact Video Series: Brain and Mind Centre

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Centre for Human Psychopharmacology

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Charlie Teo Foundation

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: MS Research Australia

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Orygen

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
November 22, 2019

Impact Video Series: Our Impact

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More